Follow us on:

Linkedin Facebook

2025

Broker Ratings

Castle Biosciences, Inc. (CSTL) Stock Analysis: Navigating the Diagnostics Frontier with Analyst Confidence

Broker Ratings

Geron Corporation (GERN) Stock Analysis: High Analyst Ratings Signal a 168% Upside Potential

Broker Ratings

Kura Oncology, Inc. (KURA) Investor Outlook: Unveiling a Potential 235% Upside with Innovative Cancer Therapies

Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 190% Upside Potential Amidst Challenging Financials

Broker Ratings

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Sector with a Unique Market Position

Broker Ratings

Xeris Biopharma Holdings, Inc. (XERS)

Broker Ratings

Valneva SE (VALN) Stock Analysis: Exploring the 58% Upside Potential in the Biotech Sector

Real Estate Credit Investments

RECI reports November NAV of 142.4p and maintains quarterly dividend

Real Estate Credit Investments reported a net asset value of 142.4 pence per share as at 30 November 2025, with the portfolio invested across 24 real estate credit positions valued at £281.9 million...
Broker Ratings

Talkspace, Inc. (TALK) Investor Outlook: A Healthcare Disruptor with 34.92% Potential Upside

Broker Ratings

AbCellera Biologics Inc. (ABCL) Stock Report: Exploring a Potential 178% Upside

Broker Ratings

Keros Therapeutics, Inc. (KROS) Investor Outlook: A 16% Upside Potential with Robust Revenue Growth

Broker Ratings

Replimune Group, Inc. (REPL) Stock Analysis: Unveiling the 29.74% Potential Upside in Biotech

Broker Ratings

Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Gem with 29% Upside Potential

Broker Ratings

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating a 55.66% Potential Upside in Biotech

Broker Ratings

KalVista Pharmaceuticals, Inc. (KALV): Analyst Consensus Reveals Over 100% Potential Upside

Broker Ratings

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring a 217.58% Potential Upside

Broker Ratings

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 239% Upside Potential in Innovative Cancer Therapies

Broker Ratings

Eton Pharmaceuticals (ETON) Investor Outlook: Exploring an 87% Potential Upside in the Rare Disease Market

Broker Ratings

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unpacking the 84.65% Potential Upside for Investors

Broker Ratings

GH Research PLC (GHRS) Stock Analysis: Exploring a 138.80% Upside in the Biotech Sector

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Broker Notes, Comments and Analysis

Broker Ratings

Castle Biosciences, Inc. (CSTL) Stock Analysis: Navigating the Diagnostics Frontier with Analyst Confidence

Broker Ratings

Geron Corporation (GERN) Stock Analysis: High Analyst Ratings Signal a 168% Upside Potential

Broker Ratings

Kura Oncology, Inc. (KURA) Investor Outlook: Unveiling a Potential 235% Upside with Innovative Cancer Therapies

Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 190% Upside Potential Amidst Challenging Financials

Broker Ratings

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Cannabis Sector with a Unique Market Position

Broker Ratings

Xeris Biopharma Holdings, Inc. (XERS)

Broker Ratings

Valneva SE (VALN) Stock Analysis: Exploring the 58% Upside Potential in the Biotech Sector

Real Estate Credit Investments

RECI reports November NAV of 142.4p and maintains quarterly dividend

Real Estate Credit Investments reported a net asset value of 142.4 pence per share as at 30 November 2025, with the portfolio invested across 24 real estate credit positions valued at £281.9 million...
Broker Ratings

Talkspace, Inc. (TALK) Investor Outlook: A Healthcare Disruptor with 34.92% Potential Upside

Broker Ratings

AbCellera Biologics Inc. (ABCL) Stock Report: Exploring a Potential 178% Upside

Broker Ratings

Keros Therapeutics, Inc. (KROS) Investor Outlook: A 16% Upside Potential with Robust Revenue Growth

Broker Ratings

Replimune Group, Inc. (REPL) Stock Analysis: Unveiling the 29.74% Potential Upside in Biotech

Broker Ratings

Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Gem with 29% Upside Potential

Broker Ratings

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating a 55.66% Potential Upside in Biotech

Broker Ratings

KalVista Pharmaceuticals, Inc. (KALV): Analyst Consensus Reveals Over 100% Potential Upside

Broker Ratings

Bicycle Therapeutics plc (BCYC) Stock Analysis: Exploring a 217.58% Potential Upside

Broker Ratings

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 239% Upside Potential in Innovative Cancer Therapies

Broker Ratings

Eton Pharmaceuticals (ETON) Investor Outlook: Exploring an 87% Potential Upside in the Rare Disease Market

Broker Ratings

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unpacking the 84.65% Potential Upside for Investors

Broker Ratings

GH Research PLC (GHRS) Stock Analysis: Exploring a 138.80% Upside in the Biotech Sector

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

2025

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple